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Evidence-Based ReviewAmong theprimary objectives of theAmericanSoci-
ety for Blood and Marrow Transplantation (ASBMT)
are to:
 Define commonly accepted medical and evidence-
based practice
 Develop standards of medical care for autologous
and allogeneic transplants
 Provide recommendations for physicians, patients,
and third-party payers on the role of transplantation
as a therapeutic approach.
Toward this end, in 1999 the Society began spon-
soring evidence-based reviews (EBRs) of the scientific
and medical literature to document when blood and
marrow transplantation is indicated in the treatment
of selected diseases.
In 2009, the ASBMT EBR Steering Committee
determined that previously published reviews should
be updated regularly, at approximately 5-year inter-
vals. The adult acute lymphoblastic leukemia (ALL)
EBR is the second in the series to be updated.
GOALS
The goals of the EBRs are to:
 Assemble and critically evaluate all valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion (SCT) related to the disease
 Provide treatment recommendations based on the
available evidence
 Identify discrepancies in study design or methodol-
ogy among published studies that may impact the
quality of the evidence
 Identify areas of needed research.
The goals of the Adult ALL EBR update are to:
 Provide a summary of recent clinical evidence
 Provide timely treatment recommendations
 Determine if new evidence strengthens or changes
treatment recommendations provided in the origi-
nal Adult ALL EBR published in 2006./$36.00
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RECOMMENDATIONS FOR ADULTALL
The following updated treatment recommenda-
tions are offered for the role of SCT as treatment for
ALL in adults, and are based on consensus reached by
an expert panel1 following a systematic reviewof the lit-
erature [1] published since the 2006 original EBR [2].Autologous SCT versus non-transplantation
Therapy for ALL in First Complete
Remission (CR1)
 New evidence indicates that in the absence of a suit-
able allogeneic donor, autologous SCT may be an
appropriate therapy because of similar survival out-
comes and a shorter treatment duration when com-
pared with chemotherapy alone, but results in a high
relapse rate. Maintenance therapy, biologic therapy,
or tyrosine kinase inhibitors may improve outcomes
in selected patients, but these approaches need
further study.Allogeneic SCT versus non-transplantation
Therapy for ALL in CR1
 New data indicate thatmyeloablative allogeneic SCT
is an appropriate treatment for adult ALL in CR1 for
all disease risk groups. Allogeneic SCTprovides a sig-
nificant improvement in overall and leukemia-free
survival in younger (\35 years), standard risk, Ph-
negative ALL patients compared with less intensive
chemotherapy regimens. In older (.35 years), stan-
dard risk, Ph-negative ALL patients, a higher
transplant-related motality diminishes the significant
survival advantage with allogeneic SCT.Allogeneic SCT versus non-transplantation for
ALL in $CR2
 New data confirm the original treatment recom-
mendation favoring allogeneic SCT over chemo-
therapy for ALL in CR2 or greater.
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 New data strengthen the original treatment recom-
mendation favoring allogeneic over autologous
SCT. There are insufficient data to determine if
this effect is more apparent in disease risk sub-
groups, including Ph1 ALL.
Related versusUnrelatedDonorAllogeneic SCT
 New data confirm the original recommendation that
there are similar, and possibly equivalent, survival
outcomes after related and unrelated allogeneic
SCT. Post-SCT complications may differ.
Unrelated Donor Cord Blood Transplant versus
Unrelated Donor BMT
 New data indicate it is appropriate to consider cord
blood transplantation for patients with no HLA-
well-matched donor option or those needing an
urgent transplant.
Imatinib versus No Imatinib Pre- and/or Post-
SCT in Ph-Positive ALL
 New data suggest imatinib therapy before and/or af-
ter SCT yields significantly superior outcomes in
overall survival and leukemia-free survival. Ongoing
studies using other tyrosine kinase inhibitors may
strengthen this recommendation.
Comparison of Induction Therapies before SCT
 New data were insufficient to make a treatment rec-
ommendation regarding the benefit of any 1 induc-
tion regimen.
Allogeneic SCT: Conditioning
 There are not enough data to make a recommenda-
tion of the superiority of any 1 conditioning regi-
men. As in the original recommendation, there
appears to be a benefit to total body irradiation-
containing regimens compared with non–total
body irradiation-containing regimens.
 New data suggest reduced-intensity conditioning
may produce similar outcomes to myeloablative
regimens, but are insufficient to make a recommen-
dation on the use of reduced-intensity conditioning.
Thus, reduced-intensity regimens are appropriate
only for adult patients with ALL in remission who
are unsuited for myeloablative conditioning.AREAS OF NEEDED RESEARCH
After reviewing the updated evidence, the expert
panel identified the following important areas of
needed research in adult ALL:1. re-evaluate allogeneic SCT versus more intensive
chemotherapy regimens, especially in younger (\35
years) adults, and in the context of biologic therapies
and tyrosine kinase inhibitors (for Ph1 ALL).
2. Assess the ability of tyrosine kinase inhibitors to re-
duce the leukemia burden pre- or post-SCT in Ph1
ALL patients and evaluate whether this can im-
prove survival outcomes after autologous and allo-
geneic SCT. Studies of different tyrosine kinase
inhibitors, doses, and schedules will be important.
3. Improvement in the detection and monitoring of
minimal residual disease during initial treatment
to guide individual patient eligibility and timing
of allogeneic SCT.
4. Monitoring of minimal residual disease after SCT
to detect early post-SCT relapse in need of preemp-
tive therapy. This may indicate patients at higher
risk of early recurrence, but effective therapy will
also need to be developed.
5. Indications for using reduced-intensity versus mye-
loablative conditioning regimens for allogeneic
SCT. The broad range of conditioning intensity
will need further study, adjusted for a patient’s tol-
erance of conditioning toxicity balanced against the
risk of relapse.
6. Evaluation of cord blood transplantation techniques,
suchas single unit, doubleunit, and ex vivo expansion,
to improve survival outcomes and reduce transplant-
related mortality. Largermulticenter experience will
be needed tomore fully evaluate the broader applica-
bility of cord blood grafting for adults with ALL.
7. Assessment of patient quality of life and functional
status after successful SCT.
8. Assess the impact of management plans and follow-
up care to facilitate better quality of life for ALL
patients, regardless of treatment.
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